​ Re-iterate Buy, but lower our TP by 2.0% to EUR 5.8/share (implying a 25.5% upside) after H1 17A results.  Solid organic growth, 20bps y/y improvement in EBIT margin in H1 17A and 12.8%/10.2% DHEPS growth in FY 18/19e, support our Buy case.  Benefits from acquisition likely to take longer to materialise. We take a more conservative view on Mattress Firm (MFRM) margin recovery due to supply disruption and store rebranding; and lower MFRM EBIT margin by 130bps/170bps in FY 17e/FY 18e....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.